Industry Outlines Concerns Over EU Proposals On Pharmaceuticals In The Environment
Executive Summary
EFPIA has generally welcomed the European Commission’s consultation on pharmaceuticals in the environment, but says it also has concerns over certain aspects of the proposals that it thinks are impracticable and could delay patient access to medicines.
You may also be interested in...
Medicines In The Environment: EU Moots Action On ‘Green’ Manufacturing, Pack Sizes, Discharges
Stakeholders in the EU are being asked to give their views on ways of addressing the problem of pharmaceuticals posing public health risks when they enter the environment via their manufacture, use and disposal. “Green” manufacturing and design, closer monitoring of discharges and more appropriate pack sizes are among proposals put forward.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.